20.99
Fulgent Genetics Inc stock is traded at $20.99, with a volume of 11,576.
It is down -2.06% in the last 24 hours and up +9.40% over the past month.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
See More
Previous Close:
$21.39
Open:
$21.49
24h Volume:
11,576
Relative Volume:
0.02
Market Cap:
$594.99M
Revenue:
$320.35M
Net Income/Loss:
$-75.01M
P/E Ratio:
-8.7622
EPS:
-2.3953
Net Cash Flow:
$-113.17M
1W Performance:
+2.10%
1M Performance:
+9.40%
6M Performance:
-25.21%
1Y Performance:
+8.61%
Fulgent Genetics Inc Stock (FLGT) Company Profile
Name
Fulgent Genetics Inc
Sector
Industry
Phone
626-350-0537
Address
4399 SANTA ANITA AVE, EL MONTE
Compare FLGT vs TMO, DHR, IDXX, NTRA, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
FLGT
Fulgent Genetics Inc
|
20.95 | 582.78M | 320.35M | -75.01M | -113.17M | -2.3953 |
|
TMO
Thermo Fisher Scientific Inc
|
518.34 | 186.32B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
194.32 | 134.82B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
IDXX
Idexx Laboratories Inc
|
571.47 | 41.53B | 4.45B | 1.10B | 1.06B | 13.59 |
|
NTRA
Natera Inc
|
281.09 | 38.88B | 2.50B | -226.32M | 71.51M | -1.6412 |
|
WAT
Waters Corp
|
377.36 | 36.82B | 3.77B | 449.25M | 240.68M | 7.8556 |
Fulgent Genetics Inc Stock (FLGT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-05-25 | Upgrade | UBS | Neutral → Buy |
| Dec-07-23 | Initiated | UBS | Neutral |
| Dec-08-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-18-22 | Initiated | Raymond James | Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Feb-04-22 | Resumed | Piper Sandler | Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Underperform |
| Jan-08-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Nov-24-20 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-20-20 | Initiated | Oppenheimer | Outperform |
| May-29-20 | Initiated | BTIG Research | Buy |
| Nov-05-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Mar-01-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Nov-07-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
View All
Fulgent Genetics Inc Stock (FLGT) Latest News
Enterprise value to EBITDA forward of Fulgent Genetics, Inc. – NASDAQ:FLGT - TradingView
Price to earnings forward of Fulgent Genetics, Inc. – NASDAQ:FLGT - TradingView
Enterprise value to EBIT forward of Fulgent Genetics, Inc. – NASDAQ:FLGT - TradingView
Enterprise value to EBIT forward of Fulgent Genetics, Inc. – BMV:FLGT - TradingView
Enterprise value to revenue forward of Fulgent Genetics, Inc. – NASDAQ:FLGT - TradingView
Price to earnings forward of Fulgent Genetics, Inc. – BMV:FLGT - TradingView
Price to book forward of Fulgent Genetics, Inc. – NASDAQ:FLGT - TradingView
Price to sales forward of Fulgent Genetics, Inc. – BMV:FLGT - TradingView
Fulgent Genetics, Inc. Actuals & Estimates (NASDAQ:FLGT) - TradingView
Fulgent Genetics Inc (FLGT) Valuation: PE, PB & Fair Value Analysis - TradingKey
How (FLGT) Movements Inform Risk Allocation Models - Stock Traders Daily
Fulgent Genetics, Inc. Actuals & Estimates (BMV:FLGT) - TradingView
FLGT Forecast — Price Target — Prediction for 2027 - TradingView
Fulgent Genetics, Inc. Actuals & Estimates (BIVA:FLGT) - TradingView
Fulgent Genetics Inc (FLGT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Fulgent Genetics (FLGT) Stock Faces Mixed Analyst Target Changes After Margin Questions - Yahoo Finance
Fulgent Genetics Inc (FLGT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Fulgent Genetics Inc (FLGT) Institutional Confidence - TradingKey
Fulgent Genetics Inc (FLGT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Fulgent Genetics Inc (FLGT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Fulgent Genetics Inc. (FLGT) Q1 2026 Earnings: EPS Miss Widens, Yet Shares Buck the TrendEarnings Cycle Report - Město Břeclav
Tranche Update on Fulgent Genetics, Inc.'s Equity Buyback Plan announced on March 8, 2022. - marketscreener.com
Fulgent Genetics Inc (FLGT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Fulgent Genetics Inc (FLGT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Fulgent Genetics Inc (FLGT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Fulgent Genetics unveils FulGenome upgrade with higher repeat expansion detection - Traders Union
Trading Systems Reacting to (FLGT) Volatility - Stock Traders Daily
Fulgent Deadline Alert - TMX Newsfile
How The Fulgent Genetics (FLGT) Investment Story Is Evolving With Recent Developments - Yahoo Finance
Fulgent Genetics Inc. (FLGT) Q1 2026 Earnings: Wide EPS Miss Sends Shares LowerEarnings Acceleration Picks - dars.gov.et
Fulgent Genetics CSO Gao Hanlin sells $30,190 in stock By Investing.com - Investing.com Australia
How Fulgent Genetics Inc. (FLGT) Affects Rotational Strategy Timing - Stock Traders Daily
Fulgent Genetics CSO Gao Hanlin sells $30,190 in stock - Investing.com
Fulgent Genetics (NASDAQ: FLGT) insider sale covers RSU taxes - Stock Titan
Fulgent Genetics (FLGT) CFO reports tax withholding of vested RSU shares - Stock Titan
Fulgent Genetics (FLGT) CSO sells 1,688 shares to cover RSU tax - Stock Titan
Fulgent (NASDAQ: FLGT) CEO RSU vest triggers 4,392-share tax withholding - Stock Titan
Fulgent Genetics (NASDAQ: FLGT) Form 144 lists 45,304 vested shares; small prior sale - Stock Titan
Fulgent Presents Updated Phase 2 FID-007 + Cetuximab Data at ASCO Showing 61.9% ORR - TradingView
Fulgent Genetics (FLGT) Presents Promising Data on Head and Neck Cancer Treatment - GuruFocus
Strong FID-007 Phase 2 results for Fulgent Genetics (NASDAQ: FLGT) - Stock Titan
Fulgent Presents Updated FID-007 Data at ASCO 2026 - The Joplin Globe
Fulgent Genetics COO Jian Xie sells $21,137 in company stock By Investing.com - Investing.com Australia
Fulgent Genetics COO Jian Xie sells $21,137 in company stock - Investing.com
Fulgent Genetics (NASDAQ: FLGT) exec sells shares for tax withholding - Stock Titan
[Form 4] Fulgent Genetics, Inc. Insider Trading Activity - Stock Titan
Fulgent Genetics (FLGT) CSO sells 945 shares to cover tax obligations - Stock Titan
Ming Hsieh (FLGT) reports 32% Fulgent Genetics stake and major share pledges - Stock Titan
Fulgent Genetics (FLGT) CEO reports RSU tax withholding and large trust holdings - Stock Titan
Fulgent Genetics (FLGT) price target decreased by 28.85% to 18.87 - MSN
FLGTFulgent Genetics Inc Stock Price and Quote - Finviz
Fulgent Genetics Inc Stock (FLGT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Fulgent Genetics Inc Stock (FLGT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gao Hanlin | Chief Scientific Officer |
Jun 02 '26 |
Sale |
17.89 |
1,688 |
30,191 |
990,374 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):